MétaCan
Menu
Back to cohort
Record W2330432678 · doi:10.1158/1538-7445.am10-5672

Abstract 5672: A novel anti-cancer effect of hesperidin: reversion of epithelial mesenchymal transition in human prostate cancer cells

2010· article· en· W2330432678 on OpenAlexaff
Yiu-Keung Lau

Bibliographic record

VenueCancer Research · 2010
Typearticle
Languageen
FieldChemistry
TopicChromatography in Natural Products
Canadian institutionsCancerCare Manitoba
Fundersnot available
KeywordsProstate cancerLNCaPHesperidinEpithelial–mesenchymal transitionCancer researchCancerMetastasisCancer cellMedicineDU145ProstateViability assayCellInternal medicinePathologyBiologyBiochemistry

Abstract

fetched live from OpenAlex

Abstract Prostate cancer is the most common noncutaneous malignancy in men. About one third of prostate cancers invade surrounding tissues, and metastasize to distant organs at the time of diagnosis. Once prostate cancer metastasizes to distant organs, the disease is basically not curable. The median survival for men with metastatic prostate cancer is 1 to 3 years. Epithelial mesenchymal transition (EMT) is a process facilitating cancer cell invasion and metastasis. Hesperidin (3′-5,7-trihydroxy-4′-methoxyflavanone 7-rhamnoglucoside) is a flavonoid found abundantly in citrus fruits. It demonstrates anti-inflammatory, anti-oxidative, and anti-proliferative actions in various cancer types. Its effect on EMT of prostate cancer is not known. We therefore hypothesize that hesperidin inhibits the cell growth and EMT of prostate cancer cells. In our study, we use androgen-sensitive prostate cancer LNCaP cells, androgen-insensitive Du 145 and PC3 cells, and benign prostate BPH-1 cells. These cell lines are treated with increasing concentrations of hesperidin, from 10 µM to 200 µM. We first examine the effects of hesperidin on cell viability by MTT assays. Hesperidin inhibits all three prostate cancer cell viability in a dose dependent manner but it has no significant effects on that of normal prostate cells, BPH-1. We then examine whether hesperidin reverses EMT in these cells by investigating the migration ability and the expression of EMT marker. Hesperidin at 100 µM and 200 µM inhibits the cell migration ability of PC3 and LNCaP as showed by wound scratch assay. Next, we examine expression of E-cadherin, a molecular marker for EMT, by immunohistochemistry. Hesperidin at 100 µM significantly enhances the membranous expression of E-cadherin in LNCaP cells after 48 hours of treatment as compared to the control. There are no significant changes in androgen receptor (AR) protein level or PSA mRNA after hesperidin treatment suggestive that the effects of hesperidin on LNCaP cells are AR-independent. In conclusions, our data provide novel findings that hesperidin can induce the reversion of EMT in prostate cancer cells. Hesperidin may therefore be a potential chemopreventive agent in human prostate cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5672.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.363
Teacher spread0.338 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2010
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicChromatography in Natural ProductsFrench-language works237,207